12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Xarelto rivaroxaban: Phase III data

The double-blind, double-dummy, international Phase III MAGELLAN trial in 8,100 hospitalized patients with acute medical illnesses showed that short- (10 days) and long-term (35 days) once-daily 10 mg oral rivaroxaban met the co-primary efficacy endpoints of non-inferiority and superiority, respectively, to once-daily 40 mg subcutaneous enoxaparin for 10 days in reducing the composite of VTE, DVT, non-fatal PE and VTE-related death. Specifically, short-term rivaroxaban was non-inferior to enoxaparin on the endpoint in the per protocol (PP) population (n=5,932; 2.7% vs. 2.7%, p=0.0025 for non-inferiority), while long-term rivaroxaban was superior to enoxaparin followed by placebo in the modified intent-to-treat...

Read the full 467 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >